In the following video, Motley Fool health-care analyst David Williamson explains what's behind a massively important trial for Vertex Pharmaceuticals (VRTX 0.59%). The company's cystic fibrosis drug Kalydeco currently treats only about 4% of the population, but Vertex is looking to apply the drug to a more common mutation of the disease, which would expand the drug's reach to be effective for nearly half of the CF patient population. David tells investors just how much money is at stake in this market, and what's at stake if the trial doesn't go as planned.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Vertex Enters Critical Phase
NASDAQ: VRTX
Vertex Pharmaceuticals

Vertex begins one of the most critical trials of the company's history.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.